Pancreatic Cancer Research

ResearcherBiognosys (Switzerland)Active in the last 2 years

Marco Tognetti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2379-1525; OpenAlex author ID A5087975857. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. Serum proteomics reveals survival-associated biomarkers in pancreatic cancer patients treated with chemoimmunotherapy. Co-author DOI 10.1016/j.isci.2025.112230↗
  2. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE… Co-author DOI 10.1038/s41591-022-01829-9↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christoph B. Messner · 1 shared paper, 2025 · strength 0.28
  2. Zev A. Wainberg · 1 shared paper, 2022 · strength 0.10
  3. Andrew H. Ko · 1 shared paper, 2022 · strength 0.10
  4. Robert A. Wolff · 1 shared paper, 2022 · strength 0.10
  5. Eileen Mary O'Reilly · 1 shared paper, 2022 · strength 0.10
  6. Lacey Padrón · 1 shared paper, 2022 · strength 0.10
  7. Robert H. Vonderheide · 1 shared paper, 2022 · strength 0.10
  8. George Albert Fisher · 1 shared paper, 2022 · strength 0.10
  9. Katelyn T. Byrne · 1 shared paper, 2022 · strength 0.10
  10. Osama E. Rahma · 1 shared paper, 2022 · strength 0.10
  11. Mark H. O’Hara · 1 shared paper, 2022 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.